Original articlePredictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab
Abbreviations and Acronyms
Cited by (0)
Supplemental material is available at www.aaojournal.org.
Financial Disclosure(s): The author(s) have made the following disclosure(s): N.L.: Employee – Genentech, Inc, (South San Francisco, CA).
P.A.C.: Consultant (institutional remuneration) – Genentech, Inc, (South San Francisco, CA); Regeneron Pharmaceuticals, Inc., (Tarrytown, NY) Aerpio (Cincinnati, OH); Consultant (personal remuneration) – Abbvie; Advanced Cell Technology (DSMC); Aerpio; Allergan (Irvine, CA); Alimera (Atlanta, GA); Applied Genetic Technologies Corporation (Gainesville, FL); Eleven (Cambridge, MA); Genentech, Inc, (South San Francisco, CA); Kala (Cambridge, MA); Regeneron Pharmaceuticals, Inc; Financial support – Genentech, Inc, (South San Francisco, CA); Regeneron Pharmaceuticals, Inc; Aerpio; Allergan; Genzyme (Cambridge, MA); Molecular Partners (Zurich, Switzerland); Oxford BioMedica (Oxford, UK); Roche (Basil, Switzerland); Equity owner – Graybug (Baltimore, MD).
Supported in part by an Association for Research in Vision and Ophthalmology (ARVO) National Eye Institute Travel Grant for presentation at ARVO 2014 (R.S.); the George S. and Dolores Doré Eccles Professorship of Ophthalmology and Neuroscience, Baltimore, MD. (P.A.C.). Genentech, Inc., participated in the design and conduct of the study and in data collection, management, analysis, and interpretation. Assistance in preparation of the figures was provided by Grace H. Lee, PharmD, and Michael P. Bennett, PhD, of Envision Scientific Solutions (Southport, CT), and funded by Genentech, Inc., (South San Francisco, CA).
Author Contributions:
Conception and design: Sophie, Lu, Campochiaro
Analysis and interpretation: Sophie, Lu, Campochiaro
Data collection: Sophie, Lu, Campochiaro
Obtained funding: Sophie, Lu, Campochiaro
Overall responsibility: Sophie, Lu, Campochiaro